Abstract: Paper microfluidic devices for testing for explosives are provided, along with methods of fabricating and using the same. One or more channels are formed on a paper substrate, and a test spot is formed in at least one of the channels. The channels can be hydrophobic. A test reagent is provided in the test spot and tests for explosives.

Abstract: An oil identification system is disclosed. The oil identification system includes a parameter sensor coupled to at least one of an oil pan or an oil flow path of a machine. The oil identification system also includes an identification module. The identification module is also configured to receive a signal indicative of movement of charged particles in the oil of the at least one of the oil pan or the oil flow path. The identification module is further configured to determine a resistivity of the oil in the at least one of the oil pan or the oil flow path. The identification module is configured to compare the resistivity of the oil with resistivity data readings. The identification module is also configured to identify a type of oil in the at least one of the oil pan or the oil flow path based on the comparison.

Abstract: A fluid filtration system may include a fluid filter assembly that includes a filter element configured to filter a fluid and a sensor probe incorporated into the fluid filter assembly. The sensor probe may include a chemically reactive material sensitive to at least one property of the fluid and at least a portion of the sensor probe may be exposed to the fluid.

Abstract: A nanodevice includes a reservoir filled with conductive fluid and a membrane separating the reservoir. A nanopore is formed through the membrane having electrode layers separated by insulating layers. A certain electrode layer has a first type of organic coating and a pair of electrode layers has a second type. The first type of organic coating forms a motion control transient bond to a molecule in the nanopore for motion control, and the second type forms first and second transient bonds to different bonding sites of a base of the molecule. When a voltage is applied to the pair of electrode layers a tunneling current is generated by the base in the nanopore, and the tunneling current travels via the first and second transient bonds formed to be measured as a current signature for distinguishing the base. The motion control transient bond is stronger than first and second transient bonds.

Abstract: Provided is an apparatus for blood analysis. The apparatus for blood analysis includes a spin coater to which blood is supplied, a light source part emitting light onto the spin coater, a measurement part detecting light reflected from the blood on the spin coater, and outputting a detected signal, and an analysis part analyzing information on the blood from the detected signal from the measurement part.

Abstract: A centrifuge is provided. The centrifuge includes a power source, the power source configured to generate electrical power from a renewable power source. At least one battery electrically coupled to the power source. A motor is electrically coupled to the at least one battery. A rotor is coupled to the motor. The rotor has a generally cylindrical body and a pair of opposing openings opposite the motor, and a pair of holders each disposed in one of the pair of opposing openings, each of the holders having an opening on one end sized to receive a capillary tube.

Abstract: A device, system and method related to a pneumatic system for fluid analysis. The device, system and method comprises a connection interface for a fluid analyser unit, a connection interface for a pump unit, a flow sensor and a pressure sensor. The device, system and method further comprises control unit for calculating a pump stroke force or amplitude, and/or pump frequency based on measurements from the flow sensor and the pressure sensor for obtaining a constant flow through the pneumatic system.

Abstract: A method of determining or predicting a characteristic of a query cell, for example the identity of the query cell, is described. The method comprises the steps of incubating the query cell with a plurality of chemical cell stressor molecules, determining the growth response of the query cell in the presence of each of the at least three chemical cell stressor molecules to generate a query cell-specific growth response fingerprint, and comparing the query cell-specific growth response fingerprint with one or more reference cell-specific growth response fingerprints corresponding to one or more cells having known characteristics. The characteristic of the cell (for example the identity of the cell) may be determined based on the level of correlation between the query cell-specific growth response fingerprint and the one or more reference cell-specific growth response fingerprints.

Abstract: A fluid channel system for examining cells may comprise a chamber filled with at least one photopolymerized hydrogel and/or one polymerized photodepolymerizable hydrogel to at least 90% capacity. The chamber may open exclusively towards at least one fluid channel via at least two openings. The at least one fluid channel and the chamber may each be in the form of a hollow space in a substrate, and each fluid channel may have two openings to the outside. In an embodiment, the system may comprise a hollow space in a substrate with at least one photopolymerized hydrogel and/or one polymerized photodepolymerizable hydrogel may be arranged and structured such that at least one fluid channel and a coherent hydrogel structure are formed. The hydrogel structure may adjoin the at least one fluid channel at two separate surface areas and connect to the outside exclusively via the at least one fluid channel.

Abstract: The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunction and for enhancing memory or normal cognitive performance (ability or function) in the animal.

Abstract: The present invention pertains to a method for screening a compound useful in reducing astroglial edema, said method comprising: (i) providing a compound; (ii) bringing said compound in contact with an astrocyte; and (iii) determining the cAMP level in said astrocyte contacted with said compound; wherein said compound is identified as a compound useful in reducing astroglial edema, if the cAMP level in the astrocyte increases after contact. The present invention further pertains to an agent elevating the cAMP level in astrocytes for use in reducing astroglial edema.

Abstract: Methods are described for phototransferring a compound from a first surface to a second surface. Compounds are described with photocleavable linkers. Compounds attached to a first surface through a photocleavable linker are put in proximity (or contact) with a second surface, and then phototransferred to the second surface upon exposure to electromagnetic radiation. Illuminating the compound with radiation photocleaves the compound from the first surface and transfers the compound to the second surface.

Abstract: A rapid test is provided for detecting pathogenic material, particularly for supporting the diagnosis of sepsis, as well as a kit and a device for the implementation of a sepsis test.

Abstract: A device (1) for use in the detection of binding affinities comprises a substrate (2) devoid of a waveguide. The substrate (2) has a planar surface (21) having arranged thereon a plurality of binding sites (31) capable of binding with a target molecule (32). The binding sites (31) are arranged along a plurality of adjacently arranged curved lines (4). The lines are spaced from one another by a distance to in operation cause a beam of coherent light (51) of a predetermined wavelength incident on the binding sites (31) with the bound target molecule (32) to be diffracted in a manner such that diffracted portions (61) interfere at a predetermined detection location (62) with a difference in optical path length which is a multiple integer of the predetermined wavelength of the coherent light. The device further comprises a beam stop (7) arranged to prevent propagation of non-diffracted portions (63) of the incident beam of coherent light (51) to the detection location (62).

Abstract: This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed.

Abstract: According to the present invention, the amount of a plasmablast (PB) in a sample of a relapsing-remitting multiple sclerosis (RRMS) patient can be measured, thereby predicting the therapeutic effect of interferon beta (IFN-?) or predicting a RRMS case for which the continuous administration of IFN-? is difficult due to the manifestation of a serious adverse reaction or the aggravation of concomitant immune disorder. In addition, the amount of PB in a sample of a RRMS patient can also be measured, thereby predicting the therapeutic effect of an IL-6 inhibitor in the treatment of RRMS. As a result, a treatment method effective for patients not suitable for IFN-? in the treatment of RRMS can be provided.

Abstract: The present invention relates to a CFI bioactivity assay designed to quantitatively measure (a) CFI bioactivity of plasma or other body fluids; and (b) bioactivity of CFI in plasma or other body fluids of a human patient afflicted by a disease that involves amyloid deposition in tissues, in particular Alzheimer disease, AMD, glaucoma, or beta-amyloid cataract formation.

Abstract: The invention relates to methods of detecting the presence or absence of autoantibodies in an individual and to related methods and kits.

Abstract: A method of identifying a compound capable of reducing or increasing the amount of the receptor for RAGE-C1q Binding comprising a) providing an amount of the compound to be tested; b) contacting the amount of the compound with C1q and RAGE; c) measuring the amount of RAGE-C1q binding in step b); d) comparing the amount of RAGE-C1q binding measured in step c) with the amount of RAGE-C1q binding measured under corresponding conditions in the absence of the compound; and e) identifying the compound as capable of reducing or increasing the amount of RAGE-C1q binding. The present invention also provides a method of treating a subject suffering from a RAGE-related disorder comprising administering to the subject a therapeutically effective amount of a compound that is a modulator of the amount of RAGE-C1q binding so as to thereby treat the subject.

Abstract: There are provided methods, and devices for assaying for a binding interaction between a protein, such as a monoclonal antibody, produced by a cell, and a biomolecule. The method may include retaining the cell within a chamber having an aperture; exposing the protein produced by the cell to a capture substrate, wherein the capture substrate is in fluid communication with the protein produced by the cell and wherein the capture substrate is operable to bind the protein produced by the cell; flowing a fluid volume comprising the biomolecule through the chamber via said aperture, wherein the fluid volume is in fluid communication with the capture substrate; and determining a binding interaction between the protein produced by the cell and the biomolecule.

Abstract: An in vitro method for determining the risk of occurrence of long-term kidney graft dysfunction in a subject comprising: a) measuring the level of CD8+ T cells having a phenotype CD45RA+/CD197?/CD27?/CD28? in a blood sample of the subject, b) comparing the level of CD8| T cells having a phenotype CD45RA|/CD197?/CD27?/CD28? measured at step a) with one or more reference values of the level of CD8+ T cells having a phenotype CD45RA+/CD197?/CD27?/CD28?, and c) determining the risk of occurrence of long-term kidney graft dysfunction in the said subject from the comparison performed at step b).

Abstract: The invention relates to methods comprising a step consisting of determining the proportion and/or the level of T regulatory lymphocytes with a CD4+ CD8??low Foxp3neg phenotype specific for Faecalibacterium prausnitzii for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing, an inflammatory bowel disease in a patient. The invention also concerns the treatment of an inflammatory bowel disease. The invention further relates to the kits that are useful in the above methods for diagnosing/prognosing an inflammatory bowel disease, and in the treatment of an inflammatory bowel disease. In a particular embodiment, the inflammatory bowel disease is the Crohn's disease.

Abstract: A method of creating cells expressing specific platelet alloantigens is disclosed. In one embodiment, the method comprises the steps of (a) combining one or more guide RNAs targeting within a platelet alloantigen target locus; (b) adding a repair template comprising a mutation in the target locus flanked by a homology arm on each side, wherein the template may additionally include a diagnostic restriction enzyme site at the target locus; (c) ligating the guide sequence of step (b) into a plasmid which also expresses a nuclease and, optionally, a selectable marker or a reporter gene; (d) transfecting pluripotent cells with the plasmid of step (c) in the presence of an HDR repair oligo; (e) cloning and testing the resulting reporter positive clones for expression of the alloantigen target of interest; and (f) culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest.

Abstract: The present invention provides an easy-to-use and higher-sensitivity immunochromatography device for an RSV, the device using an antibody that binds specifically to F protein of the RSV in a determination region of a chromatography medium, a test kit by an immunochromatography method, and a method for detecting an RSV using these device and kit. The present invention relates to an immunochromatography device in which not only an antibody that binds specifically to F protein of an RSV but also an antibody that binds specifically to N protein of the RSV is solid-phased in a determination region of a chromatography medium. The present invention also relates to a test kit by an immunochromatography method, and a method for detecting an RSV using these device and kit.

Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.

Abstract: The present invention provides methods of treating cancer by inhibiting MECP2 and identifying cancers that will respond to therapy using MECP2 as a biomarker.

Abstract: This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14+ cells and proceeding with a cancer treatment option (e.g., a renal cell carcinoma treatment option) based on the presence, absence, or level of CD14+ cells present within the tumor or peritumoral tissue are provided.

Abstract: The invention related to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (PDAC); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combination treatment with a nucleoside analogue (preferably gemcitabine) and with a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma.

Abstract: Methods for detecting cancer or monitoring cancer progression in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6. Also disclosed is a kit for detecting cancer or monitoring cancer progression.

Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression of cavcolin-1, cavcolin-2, vimentin, calponon2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.

Abstract: Embodiments of the present disclosure relate generally to reporter compositions which are synthetic nucleotides that comprise nucleotides with a high charge mass moiety attached thereto via a linker molecule. The linker molecules can vary in length in part to enable the high charge mass moiety to extend out from a DNA polymerase complex so that polymerization may not be influenced.

Abstract: The present invention provides a method for the analysis of a compound with amino group (e.g., an amino acid or peptide) contained in a sample and convenient manner with a high sensitivity. The compound with amino group in a sample containing the compound with amino group is labeled with a specific carbamate compound such as p-trimethylammonium anilyl-N-hydroxysuccinimidyl carbamate iodide to enhance the selectivity and sensitivity. The present invention is preferably used in conjunction with mass spectrometry such as MS/MS method to facilitate quantitative analysis. The present invention further provides labeling reagents for mass spectrometry.

Abstract: The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a ?-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a ?-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a ?-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a ?-lactmase or instructions for using the components in an assay.

Abstract: Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described.

Abstract: The invention refers to a nanoparticle comprising (i) a core comprising a first population of quantum dots (QDs) embedded in silica, (ii) a shell comprising a second population of QDs embedded in silica, (iii) at least one biomolecule selected from a peptide, a nucleic acid, a carbohydrate or a lipid which comprises a cleavage site that is susceptible of being cleaved by a hydrolytic enzyme, said biomolecule being bound to the surface of the shell through a moiety, and (iv) a photoluminescent label for each biomolecule, wherein the label is bound to the part of the biomolecule which detaches from the nanoparticle after cleavage of said biomolecule by a hydrolytic enzyme, wherein the first and second QD populations have different maximum photoluminescence emission wavelengths, and only the second QD population is susceptible of producing Forster resonance energy transfer (FRET) with the photoluminescent label.

Abstract: The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L. or less of a legacy clinical sample.

Abstract: The present invention provides set of two or more mass labels, wherein each mass label in the set has the same integer mass as every other label in the set, and each mass label in the set has an exact mass which is different to the mass of all other mass labels in the set such that all the mass labels in the set are distinguishable from each other by mass spectrometry.

Abstract: Methods of imaging a biological sample by mass cytometry using molecular tagging are disclosed.

Abstract: The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Abstract: Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.

Abstract: Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (PEG)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (PAL), such as Anabaena variabilis (Av) PAL administered to the patient as part of an enzyme substitution therapy for diseases or disorders, such as phenylketonuria (PKU), or cancer therapy.

Abstract: Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.

Abstract: Methods of stratifying a subject having or at risk for developing adolescent idiopathic scoliosis (AIS) into diagnostically or clinically useful subclasses are provided. The stratification is based on the subject's Gi? protein serine phosphorylation profile and/or the degree of imbalance in G-protein coupled receptor responses to Gi? and Gs? protein stimulation. In some embodiments, the methods involve detecting or determining the level of serine phosphorylated Gi?1 and/or Gi?3 proteins in the cell sample, and/or determining a ratio between the response to Gi? protein stimulation and the response to Gs? protein stimulation from a biological sample from the subject. Methods for predicting the risk of an AIS subject for developing a severe scoliosis, for predicting the subject's responsiveness to bracing treatment, and for identifying therapeutically useful compounds are also provided, as well as kits therefor.

Abstract: The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.

Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Abstract: Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (NASH) measuring CHI3L1 levels. In some embodiments, the methods described herein can distinguish NASH from nonalcoholic fatty liver disease. CHI3L1 levels can also be used to monitor treatment progress in patients having NASH. Also disclosed herein are compositions and methods for treating NASH by targeting CHI3L1.

Abstract: The present invention provides methods for diagnosing a neurological disease in a subject, screening for or assessing the risk of developing a neurological disease in a subject, monitoring progression of a neurological disease in a subject, assessing efficacy of a therapy for a neurological disease in a subject, and identifying a subject suffering from a neurological disease that may be successfully treated by an agent that affects levels of a biomarker such as a tau protein or an amyloid beta. The methods generally feature (a) obtaining a cerebrospinal fluid (CSF) sample from a subject; (b) providing a cerebrospinal fluid (CSF) correction factor for CSF obtained from a subject for at least one biomarker; and (c) determining whether the biomarker is present in elevated amounts or concentrations in the cerebrospinal fluid (CSF) sample. The neurological disease may be, for instance, impaired cognition or dementia such as Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI).

Abstract: The present invention provides a method for diagnosing or assessing a neurodegenerative disease in a test subject, comprising: (i) providing a protein-containing sample that has been obtained from the test subject; (ii) determining the concentration, amount or degree of expression of at least one specific protein isoform and/or glycoform derived from a protein biomarker selected from the group consisting of: clusterin precursor; apolipoprotein A-IV precursor; apolipoprotein C-III precursor; transthyretin; galectin 7; complement C4 precursor; alpha-2-macroglobulin precursor; Ig alpha-1 chain C; histone 2B; Ig lambda chain C region; fibrinogen gamma chain precursor; complement factor H; inter-alpha-trypsin heavy chain H4 precursor; complement C3 precursor; gamma or beta actin; haptoglobin precursor; and the serum albumin precursor, or a fragment thereof; (iii) comparing said concentration, amount or degree determined in (ii) with a reference from a control subject with a specific neurodegenerative disease, deme